Johnson, D. B., Nebhan, C. A., Moslehi, J. J. & Balko, J. M. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat. Rev. Clin. Oncol. 19, 254–267 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Marin-Acevedo, J. A. et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J. Hematol. Oncol. 11, 39 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Jin, S. et al. Emerging new therapeutic antibody derivatives for cancer treatment. Signal. Transduct. Target. Ther. 7, 39 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. H. I. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug. Discov. 18, 585–608 (2019).

Article  CAS  PubMed  Google Scholar 

van de Donk, N. W. C. J. & Zweegman, S. T-cell-engaging bispecific antibodies in cancer. Lancet 402, 142–158 (2023).

Article  PubMed  Google Scholar 

Klein, C., Brinkmann, U., Reichert, J. M. & Kontermann, R. E. The present and future of bispecific antibodies for cancer therapy. Nat. Rev. Drug. Discov. 23, 301–319 (2024).

Article  CAS  PubMed  Google Scholar 

Goebeler, M. E., Stuhler, G. & Bargou, R. Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nat. Rev. Clin. Oncol. 21, 539–560 (2024).

Article  PubMed  Google Scholar 

Przepiorka, D. et al. FDA approval: blinatumomab. Clin. Cancer Res. 21, 4035–4039 (2015).

Article  CAS  PubMed  Google Scholar 

Deshaies, R. J. Multispecific drugs herald a new era of biopharmaceutical innovation. Nature 580, 329–338 (2020).

Article  CAS  PubMed  Google Scholar 

Saez-Ibanez, A. R., Upadhaya, S. & Campbell, J. Immuno-oncology clinical trials take a turn beyond PD1/PDL1 inhibitors. Nat. Rev. Drug. Discov. 22, 442–443 (2023).

Article  CAS  PubMed  Google Scholar 

Saez-Ibañez, A. R., Sommers, E., Upadhaya, S. & Campbell, J. PD1/PDL1 clinical trials adapt to a growing landscape of patients resistant to PDx. Nat. Rev. Drug. Discov. 22, 944–945 (2023).

Article  PubMed  Google Scholar 

Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836–847 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stein, A. S. et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann. Hematol. 98, 159–167 (2019).

Article  CAS  PubMed  Google Scholar 

Frey, N. V. & Porter, D. L. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Am. Soc. Hematol. Educ. Program. 2016, 567–572 (2016).

Article  Google Scholar 

Li, H., Er Saw, P. & Song, E. Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics. Cell Mol. Immunol. 17, 451–461 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sun, D., Gao, W., Hu, H. & Zhou, S. Why 90% of clinical drug development fails and how to improve it? Acta Pharm. Sin. B. 12, 3049–3062 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Irani, V. et al. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol. Immunol. 67, 171–182 (2015).

Article  CAS  PubMed  Google Scholar 

Saunders, K. O. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front. Immunol. 10, 1296 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zinn, S. et al. Advances in antibody-based therapy in oncology. Nat. Cancer 4, 165–180 (2023).

Article  PubMed  Google Scholar 

Edwards, C. J. et al. The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. Br. J. Cancer 126, 1168–1177 (2022).

Article  CAS  PubMed  Google Scholar 

Archer, S. et al. CB307: a dual targeting costimulatory Humabody VH therapeutic for treating PSMA-positive tumors. Clin. Cancer Res. 30, 1595–1606 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Power, C. A. & Bates, A. David vs. Goliath: the structure, function, and clinical prospects of antibody fragments. Antibodies 8, 28 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E. & de Groot, D. J. A. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol. Ther. 201, 103–119 (2019).

Article  CAS  PubMed  Google Scholar 

Al Ojaimi, Y. et al. Therapeutic antibodies – natural and pathological barriers and strategies to overcome them. Pharmacol. Ther. 233, 108022 (2022).

Article  CAS  PubMed  Google Scholar 

Bensch, F. et al. Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers – the first step towards an imaging warehouse. Theranostics 8, 4295–4304 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu, G. et al. Predicting therapeutic antibody delivery into human head and neck cancers. Clin. Cancer Res. 26, 2582–2594 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dennis, M. S. et al. Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res. 67, 254–261 (2007).

Article  CAS  PubMed  Google Scholar 

Mir, O. et al. Pharmacokinetics/pharmacodynamic (PK/PD) relationship of therapeutic monoclonal antibodies used in oncology: what’s new? Eur. J. Cancer 128, 103–106 (2020).

Article  CAS  PubMed  Google Scholar 

Ryman, J. T. & Meibohm, B. Pharmacokinetics of monoclonal antibodies. Clin. Pharmacokinet. 6, 493–507 (2017).

Google Scholar 

Keizer, R. J., Huitema, A. D. R., Schellens, J. H. M. & Beijnen, J. H. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin. Pharmacokinet. 49, 493–507 (2010).

Article  CAS  PubMed  Google Scholar 

Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715–725 (2007).

Article  CAS  PubMed  Google Scholar 

Sharma, S. K. et al. Fc-mediated anomalous biodistribution of therapeutic antibodies in immunodeficient mouse models. Cancer Res. 78, 1820–1832 (2018).

Article